Aethlon completes human safety study of Hemopurifier for kidney failure

By Lisa Kerner

Erie, Pa., April 19 - Aethlon Medical, Inc. said it successfully completed a safety study of patients treated with the Aethlon Hemopurifier at the Apollo Hospital in Delhi, India.

The company plans to use the study data to submit a Pandemic Influenza and class A Biological Weapon regulatory filing to the Food and Drug Administration.

A total of four patients met the requirements for enrollment in the study: end-stage renal disease and Hepatitis-C (HCV) infection. Patients were given six four-hour treatments with the Hemopurifier over a two-week period.

Researchers observed an approximate 30% capture of circulating HCV during each examined four-hour treatment.

"The completion of our first human study represents our most significant milestone to date," chairman and chief executive officer James A. Joyce said in a company news release.

"The recruitment of patients meeting the criteria of being afflicted with both kidney failure and Hepatitis-C did cause significant delay. However, the demonstration of safety in individuals with such severely compromised health conditions will be considerably more valuable to our efforts moving forward."

Aethlon is a medical device company located in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.